Early Access — free while we kick the tires
TLX
Telix Pharmaceuticals Ltd Insider Trading
Latest: MD & Group CEO Bought $997K of Shares · Apr 2026
The only insider purchase or sale analyzed for Telix Pharmaceuticals Ltd (TLX) so far is MD & Group CEO Behrenbruch Christian, who bought $997K in Apr 2026.
1 filing analyzed
·
Latest 2026-05-06
Get alerts for TLX
Free Form 4 email alerts, scored for significance — see how.
High conviction
This is a high-conviction signal — the insider is a first-time or occasional buyer, historically the strongest subset. Such buys have outperformed the S&P 500 by a median ~3% over the 30 days after the trade (n ≈ 3,001, 2024-2026). Past results don't predict the future. How we measure this ↗
May 2026
67,935 shares
$996,738
@ $14.67
CEO Christian Behrenbruch purchases ~68k shares in two tranches totaling ~$997k at Telix Pharmaceuticals
Christian Behrenbruch, MD and Group CEO of Telix Pharmaceuticals, deployed nearly $1 million in open-market share purchases over two trading days, acquiring approximately 68,000 shares. As the chief executive, Behrenbruch is in a position with direct operational knowledge of the company and has chosen to commit personal capital rather than rely solely on compensation. The transaction represents material personal investment by the highest-ranking executive, moving beyond routine equity compensation. While both purchases occurred at modest price levels, the filing records the factual activity: a C-suite officer making significant equity purchases in his own company within a short timeframe.
More Chemicals and Allied Products companies
